The University of Southampton
University of Southampton Institutional Repository

Chronic lymphocytic leukaemia: Correction

Chronic lymphocytic leukaemia: Correction
Chronic lymphocytic leukaemia: Correction
Nature Reviews Disease Primers 3, 16096 (2017)

In the version of the article originally published, a typographical error has now been corrected. The statement now reads: Approval of ibrutinib as initial therapy was based on the results of a randomized trial that showed a significant improvement in median PFS and overall survival in patients. ≥65 years of age without del(17p) who were treated indefinitely with ibrutinib than in patients treated for up to 48 weeks with chlorambucil146.
Kipps, Thomas J.
0fd44186-1f31-4fc9-aa1e-c7bcf9094258
Stevenson, Freda K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
Wu, Catherine J.
ccfe9fd3-5487-4b67-a02c-6e34ae3d39a4
Croce, Carlo M.
309d71ed-c41e-420a-b0bf-d53d5a8caa91
Packham, Graham
fdabe56f-2c58-469c-aadf-38878f233394
Wierda, William G.
a3df6934-fb1c-4b26-86fd-34728b0e4cdc
O'brien, Susan
6dde4fb1-1fe4-4593-b82a-3d46177816ad
Gribben, John
d442ac5b-2cc3-469c-9222-a92a46584a8d
Rai, Kanti
e9798f67-6b49-4292-884f-f8123e8c2647
Kipps, Thomas J.
0fd44186-1f31-4fc9-aa1e-c7bcf9094258
Stevenson, Freda K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
Wu, Catherine J.
ccfe9fd3-5487-4b67-a02c-6e34ae3d39a4
Croce, Carlo M.
309d71ed-c41e-420a-b0bf-d53d5a8caa91
Packham, Graham
fdabe56f-2c58-469c-aadf-38878f233394
Wierda, William G.
a3df6934-fb1c-4b26-86fd-34728b0e4cdc
O'brien, Susan
6dde4fb1-1fe4-4593-b82a-3d46177816ad
Gribben, John
d442ac5b-2cc3-469c-9222-a92a46584a8d
Rai, Kanti
e9798f67-6b49-4292-884f-f8123e8c2647

Kipps, Thomas J., Stevenson, Freda K., Wu, Catherine J., Croce, Carlo M., Packham, Graham, Wierda, William G., O'brien, Susan, Gribben, John and Rai, Kanti (2017) Chronic lymphocytic leukaemia: Correction. Nature Reviews Disease Primers, 3, [17008]. (doi:10.1038/nrdp.2017.8).

Record type: Article

Abstract

Nature Reviews Disease Primers 3, 16096 (2017)

In the version of the article originally published, a typographical error has now been corrected. The statement now reads: Approval of ibrutinib as initial therapy was based on the results of a randomized trial that showed a significant improvement in median PFS and overall survival in patients. ≥65 years of age without del(17p) who were treated indefinitely with ibrutinib than in patients treated for up to 48 weeks with chlorambucil146.

This record has no associated files available for download.

More information

Accepted/In Press date: 31 January 2017
e-pub ahead of print date: 9 February 2017
Published date: 9 February 2017

Identifiers

Local EPrints ID: 421828
URI: http://eprints.soton.ac.uk/id/eprint/421828
PURE UUID: 4172a548-2b34-47e6-9e85-d3f3e8cabdfa
ORCID for Freda K. Stevenson: ORCID iD orcid.org/0000-0002-0933-5021
ORCID for Graham Packham: ORCID iD orcid.org/0000-0002-9232-5691

Catalogue record

Date deposited: 29 Jun 2018 16:30
Last modified: 16 Mar 2024 03:14

Export record

Altmetrics

Contributors

Author: Thomas J. Kipps
Author: Catherine J. Wu
Author: Carlo M. Croce
Author: Graham Packham ORCID iD
Author: William G. Wierda
Author: Susan O'brien
Author: John Gribben
Author: Kanti Rai

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×